Fact CheckerSign in

NCT02490748Active, not recruitingPhase 2

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer

Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer

Source: ClinicalTrials.gov · Last updated 23 Feb 2016

Brief summary (registry, in English)

The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cervical cancer.

Status (registry)
Active, not recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
10 (actual)
First submitted
2 Jul 2015
Start date
Jul 2015
Primary completion date
Jun 2038
Lead sponsor
The First People's Hospital of Changzhou
NCT number
NCT02490748

What you commit to

  • Study type: Interventional · Phase 2
  • Participants enrolled: 10
  • From Jul 2015 to the primary completion date, Jun 2038
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • studies evaluating the role of radiotherapy administered with chemotherapy, or second- or subsequent-line therapy options.

Who the study is looking for

  • They were systematic reviews based on randomized controlled trials (rcts). They were phase II rcts comparing chemotherapy with other systemic therapy agents or with no further treatment for recurrent, metastatic, or persistent cervical cancer.
    • they reported at least one of these outcomes: complete or partial response rate, overall or progression-free survival rate, adverse effects, or healthrelated quality of life (rcts reporting on heterogeneous populations-for example, women at a range of disease stages-were included if results were given separately for patients with recurrent, metastatic, or persistent cervical cancer).

Age in the registry: 30 years to 70 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.